MedTrace Logo

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

NCT06030375 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-09-11

No results posted yet for this study

Summary

The study was planned to consist of 24 healthy subjects in 3 dosing cohorts receiving a continuous i.v. infusion of KAND567 or placebo for 6 h (6 subjects on active and 2 subjects on placebo per cohort), with the option of two additional cohorts of the same size and group composition.

Conditions

  • Healthy

Interventions

DRUG

KAND567

Continuous intravenous infusion for 6 hours

OTHER

Placebo

Continuous intravenous infusion for 6 hours

Sponsors & Collaborators

  • Novakand Pharma AB

    lead INDUSTRY

Principal Investigators

  • Mika Scheinin, MD, PhD · Clinical Research Services Turku (CRST)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-17
Primary Completion
2020-04-27
Completion
2020-04-27

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06030375 on ClinicalTrials.gov